百令胶囊联合厄贝沙坦治疗糖尿病肾病的效果及对微炎症和肾功能的影响  

Effect of Bailing capsule combined with irbesartan in the treatment of diabetic nephropathy and its influence on microinflammation and renal function

作　　者：陆阳 LU Yang(Jinxi People's Hospital,Kunshan 215324,China)

机构地区：[1]昆山市锦溪人民医院,215324

出　　处：《中国实用医药》2025年第4期114-117,共4页China Practical Medicine

摘　　要：目的评价糖尿病肾病患者采用百令胶囊+厄贝沙坦治疗的效果及对微炎症、肾功能的影响。方法60例糖尿病肾病患者,按照双盲法分为对照组与观察组,每组30例。对照组予以单一厄贝沙坦治疗,观察组予以百令胶囊+厄贝沙坦治疗。比较两组用药不良反应发生率及治疗前后的微炎症指标[白细胞介素-6(IL-6)、肿瘤坏死因子-α(TNF-α)、C反应蛋白(CRP)]、肾功能指标[尿素氮(BUN)、血肌酐(SCr)、β2-微球蛋白(β2-MG)]、血糖指标(空腹血糖、餐后2h血糖、糖化血红蛋白)、血脂指标[总胆固醇(TC)、甘油三酯(TG)]。结果与对照组的(10.27±1.08)mg/L、(50.36±4.07)ng/L、(15.27±1.89)ng/L相比,观察组治疗后的CRP(6.03±0.89)mg/L、TNF-α(40.93±2.28)ng/L、IL-6(12.13±1.28)ng/L均更低(P<0.05)。治疗后,观察组的BUN(5.54±1.06)mmol/L、SCr(64.79±7.61)μmol/L、β2-MG(1.46±0.23)μg/ml较对照组的(7.58±1.26)mmol/L、(70.46±8.02)μmol/L、(2.21±0.30)μg/ml更低(P<0.05)。治疗后,观察组空腹血糖(6.44±2.21)mmol/L、餐后2 h血糖(8.37±2.46)mmol/L、糖化血红蛋白(6.25±1.12)%均低于对照组的(9.79±2.77)mmol/L、(12.12±3.46)mmol/L、(8.02±1.44)%(P<0.05)。治疗后,观察组TC(4.91±0.55)mmol/L、TG(1.57±0.30)mmol/L均低于对照组的(5.89±1.04)、(2.01±0.35)mmol/L(P<0.05)。观察组用药不良反应发生率3.33%低于对照组的10.00%,但无差异性(χ^(2)=1.071,P=0.301>0.05)。结论百令胶囊与厄贝沙坦联合使用,能有效减轻糖尿病肾病患者的微炎症状态,改善肾功能,降低血糖、血脂,减缓病程进展。Objective To evaluate the effect of Bailing capsule combined with irbesartan in the treatment of diabetic nephropathy and its influence on microinflammation and renal function.Methods 60 patients with diabetic nephropathy were divided into control group and observation group according to double-blind method,with 30 cases in each group.The control group was treated with single irbesartan,and the observation group was treated with Bailing capsule+irbesartan.Both groups were compared in terms of incidence of adverse drug reactions and microinflammatory indexes[interleukin-6(IL-6),tumor necrosis factor-α(TNF-α),C-reactive protein(CRP)],renal function indexes[blood urea nitrogen(BUN),serum creatinine(SCr),β2-microglobulin(β2-MG)]and blood glucose indexes(fasting blood glucose,2-h postprandial blood glucose,glycated hemoglobin),blood lipid index[total cholesterol(TC),triglyceride(TG)]before and after treatment.Results Compared with(10.27±1.08)mg/L,(50.36±4.07)ng/L and(15.27±1.89)ng/L in the control group,CRP(6.03±0.89)mg/L,TNF-α(40.93±2.28)ng/L and IL-6(12.13±1.28)ng/L were all lower in the observation group after treatment(P<0.05).After treatment,the observation group had BUN of(5.54±1.06)mmol/L,SCr of(64.79±7.61)μmol/L,andβ2-MG of(1.46±0.23)μg/ml,which were lower than(7.58±1.26)mmol/L,(70.46±8.02)μmol/L,and(2.21±0.30)μg/ml in the control group(P<0.05).After treatment,the fasting blood glucose,2 h postprandial blood glucose and glycated hemoglobin were(6.44±2.21)mmol/L,(8.37±2.46)mmol/L and(6.25±1.12)%in the observation group,which were lower than(9.79±2.77)mmol/L,(12.12±3.46)mmol/L and(8.02±1.44)%in the control group(P<0.05).After treatment,the observation group had TC of(4.91±0.55)mmol/L and TG of(1.57±0.30)mmol/L,which were lower than(5.89±1.04)and(2.01±0.35)mmol/L in the control group(P<0.05).The incidence of adverse drug reactions of 3.33%in the observation group was lower than 10.00%in the control group,but there was no difference(χ^(2)=1.071,P=0.301>0.05).Conclusion The combinat

关 键 词：百令胶囊 厄贝沙坦 糖尿病肾病 微炎症 肾功能 

分 类 号：R58[医药卫生—内分泌]